Preethi Sankaran

Fulcrum Therapeutics (United States) — United States

Medicine · Health Sciences

5h-index199citations18works1.82yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(11), CAR-T cell therapy research(9), Radiopharmaceutical Chemistry and Applications(4), Immunotherapy and Immune Responses(3), Cancer, Stress, Anesthesia, and Immune Response(3)

Publications18 total

CBX–663, a novel TCR-mimetic T-cell engager targeting a telomerase reverse transcriptase (TERT) peptide-HLA complex, that exhibits potent efficacy against AML cells
Blood·2025
1299 Tri-specific T cell engager (TCE) targeting cathepsin G peptide-HLA (pHLA) complex with enhanced antileukemic activity via proprietary CD28 co-stimulation
Regular and Young Investigator Award Abstracts·2025Open Access
Abstract 3507: Discovery and preclinical characterization of novel TCR-mimetic T-cell engagers targeting TERT peptide-HLA complex for the treatment of solid and hematologic malignancies
Cancer Research·2025
CBX250 Is a Novel Cathepsin G Peptide-HLA-Targeting T Cell Engager That Exhibits High Tumor Antigen Selectivity and Potent Antileukemic Activity In Vivo
Blood·2024· 1 citedOpen Access
Abstract 1236: Characterization of CBX-250, a first-in-class TCR-mimetic-based T-cell engager targeting a cathepsin G peptide-HLA complex for the treatment of myeloid leukemia
Cancer Research·2024· 1 cited
Comparing anti-tumor and anti-self immunity in a patient with melanoma receiving immune checkpoint blockade
Journal of Translational Medicine·2024· 9 citedOpen Access
Abstract 4159: The COX-2/PGE2 pathway as a mediator of resistance to anti-PD-1 therapy
Cancer Research·2023· 4 cited
288 The COX-2 pathway as a mediator of resistance to anti-PD-1 therapy
Regular and Young Investigator Award Abstracts·2021· 4 citedOpen Access
Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release
Journal for ImmunoTherapy of Cancer·2021· 65 citedOpen Access
A bispecific antibody agonist of the IL-2 heterodimeric receptor preferentially promotes in vivo expansion of CD8 and NK cells
Scientific Reports·2021· 34 citedOpen Access
Effect of modulation of CD3 binding in a PSMAxCD3 T-cell engaging bispecific antibody on maintenance of efficient tumor cell kill and cytokine release.
Journal of Clinical Oncology·2020· 1 cited
Abstract 1554: Uncoupling tumor-cell cytotoxicity from cytokine release with novel T-cell engaging bispecific antibodies
Immunology·2019
Abstract 1554: Uncoupling tumor-cell cytotoxicity from cytokine release with novel T-cell engaging bispecific antibodies
Cancer Research·2019
Evaluation of monovalent versus biparatopic CD3xPSMA bispecific antibodies for t-cell mediated killing of prostate tumor cells with minimal cytokine release.
Journal of Clinical Oncology·2019
A novel CD3xPSMA bispecific antibody for efficient T cell mediated killing of prostate tumor cells with minimal cytokine release.
Journal of Clinical Oncology·2019· 2 cited
Crystal Structure of Human BCMA in complex with UniAb(TM) VH
2019· 37 citedOpen Access
Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies
Frontiers in Immunology·2019· 40 citedOpen Access
A Novel Fully Human Bispecific CD19 x CD3 Antibody That Kills Lymphoma Cells with Minimal Cytokine Secretion
Blood·2018· 1 cited

Frequent Co-authors

Kevin Dang(9), Starlynn Clarke(9), Katherine E. Harris(9), Ute Schellenberger(9), Nathan D. Trinklein(9), Aarti Balasubramani(8), Laura Davison(8), Duy Pham(8), Harshad S. Ugamraj(8), Andrew Boudreau(7), Roland Buelow(7), Ben Buelow(7), Brett Jorgensen(7), Shelley Force Aldred(7), Wim van Schooten(6), Suhasini Iyer(5), Geraldine L. C. Paulus(5), Tanzila Rahman(5), Delainey O’Connor(5), Melissa J. Bikowitz(5)